KMCRIC

With recent advances and approvals of immuno-oncology (IO) agents, pharmaceutical companies are striving to strategize and to allocate necessary resources to IO discovery, as well as to the clinical development and commercialization efforts in this exploding therapeutic area. Cambridge Healthtech Institute’s Inaugural IO Pharma Congress is designed to bring together major stakeholders from biopharmaceutical companies to discuss challenges and solutions in the areas of emerging IO targets and modalities, combination immune therapy, clinical trials, biomarkers, business strategy and more. The Congress is part of Cambridge Healthtech Institute’s World Pharma Week: the premier meeting place for pharmaceutical decision makers!